A Phase 1/2 interventional study of EFB0027 (metformin delayed release) and EFB0026 (metformin immediate-release) in Type 2 Diabetes Mellitus, sponsored by Elcelyx Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-09-20.
Sponsored by Elcelyx Therapeutics, Inc. · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States — 344 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,378th largest by enrollment of the 2,960 interventional ones that give a count, is one of 142 that started in 2012, is one of 41 in phase 1/2, and was the 1,320th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →344 of the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Pfizer · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
Rahul Sachdeva · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 19 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,307 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 425 · Phase 2 465 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 142 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,960 interventional studies, 128 across the 336 observational. Of the 2,650 that completed or were terminated, 1,165 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,489 of 3,307 have an industry lead sponsor. The 10 most frequent:
Elcelyx Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Elcelyx Therapeutics, Inc. has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
187 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 187 to your calendar (.ics) → With an account.
Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate how EFB0027 and EFB0026 behave in subjects with type 2 diabetes mellitus.
In addition, this study will compare the effects of EFB0027 and EFB0026 on circulating concentrations of glucose and gastrointestinal hormones in subjects with type 2 diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Is diagnosed with Type 2 Diabetes Mellitus with
between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with:
i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at Visit 1) of DPP-4 inhibitor alone, OR
Is male, or is female and meets all of the following criteria:
Exclusion Criteria:
Has a medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BID
Drug: EFB0026 (metformin immediate-release)
BID
Drug: EFB0027 (metformin delayed release)
BID
Drug: EFB0027 (metformin delayed release)
BID
Drug: EFB0027 (metformin delayed release) · Drug: EFB0026 (metformin immediate-release)
Comparison of enteric-coating to assess effect on PK
Also known as: Met DR
Active comparator
Also known as: Met IR, metformin, Glucophage
Area Under the Curve (0-t) of Plasma Metformin
Measures from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration. The dose of study medication was administered at t = -1 min relative to the start time of the standardized breakfast.
Time frame: Time points at which data were collected to create the area under the curve (0-t) for plasma metformin were: t = -0.08, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 11 h relative to the start time of the standardized breakfast.
Change in Fasting Plasma Glucose
LS mean difference from Baseline (Day 1) to Day 5
Time frame: Change from Baseline (Day 1) to Day 5
Within Treatment Comparison Based on Ratios of AUCs of GLP-1
Time frame: Ratio of Day 5 to Baseline
Within Treatment Comparison Based on Ratios of AUCs of PYY
Time frame: Ratio of Day 5 to Baseline
| Milestone | Sequence 1: BCAD | Sequence 2: ABDC | Sequence 3: CDBA | Sequence 4: DACB |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 3 | 5 | 5 |
| Not completed | 0 | 3 | 1 | 1 |
| Withdrew: Adverse event | 0 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 |
Measures from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration. The dose of study medication was administered at t = -1 min relative to the start time of the standardized breakfast.
| ng*h/mL | 1000 mg EFB0026 | 1000 mg EFB0027 | 500 mg EFB0027 | 500 mg EFB0026 + 1000 mg EFB0027 |
|---|---|---|---|---|
| Area Under the Curve (0-t) of Plasma Metformin | 8672 ± 29.7 | 4774 ± 29.9 | 3842 ± 37.6 | 8075 ± 38.6 |
LS mean difference from Baseline (Day 1) to Day 5
| mg/dL | 1000 mg EFB0026 | 1000 mg EFB0027 | 500 mg EFB0027 | 500 mg EFB0026 + 1000 mg EFB0027 |
|---|---|---|---|---|
| Change in Fasting Plasma Glucose | -22.5 ± 6.8 | -19.9 ± 5 | -16.4 ± 3.8 | -21.2 ± 4.7 |
| none (values are ratios) | 1000 mg EFB0026 | 1000 mg EFB0027 | 500 mg EFB0027 | 500 mg EFB0026 + 1000 mg EFB0027 |
|---|---|---|---|---|
| Within Treatment Comparison Based on Ratios of AUCs of GLP-1 | 1.87 ± 0.18 | 1.62 ± .11 | 1.69 ± .15 | 1.88 ± .19 |
| none (values are ratios) | 1000 mg EFB0026 | 1000 mg EFB0027 | 500 mg EFB0027 | 500 mg EFB0026 + 1000 mg EFB0027 |
|---|---|---|---|---|
| Within Treatment Comparison Based on Ratios of AUCs of PYY | 1.55 ± .09 | 1.38 ± .09 | 1.46 ± .06 | 1.49 ± .06 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1000 mg EFB0026 BID | — | 0/22 (0%) | 6/22 (27.3%) |
| 1000 mg EFB0027 BID | — | 1/20 (5%) | 5/20 (25%) |
| 500 mg EFB0027 BID | — | 0/20 (0%) | 4/20 (20%) |
| 500 mg EFB0026 BID Plus 1000 mg EFB0027 BID | — | 0/21 (0%) | 10/21 (47.6%) |
| Event | 1000 mg EFB0026 BID | 1000 mg EFB0027 BID | 500 mg EFB0027 BID | 500 mg EFB0026 BID Plus 1000 mg EFB0027 BID |
|---|---|---|---|---|
| Gastrointestinal Stromal TumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/22 | 1/20 | 0/20 | 0/21 |
| Event | 1000 mg EFB0026 BID | 1000 mg EFB0027 BID | 500 mg EFB0027 BID | 500 mg EFB0026 BID Plus 1000 mg EFB0027 BID |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/22 | 3/20 | 2/20 | 7/21 |
| NauseaGastrointestinal disorders | 2/22 | 0/20 | 0/20 | 3/21 |
| DizzinessNervous system disorders | 3/22 | 0/20 | 0/20 | 0/21 |
| VomitingGastrointestinal disorders | 2/22 | 0/20 | 0/20 | 0/21 |
| HeadacheNervous system disorders | 2/22 | 1/20 | 1/20 | 0/21 |
| Abdominal PainGastrointestinal disorders | 0/22 | 0/20 | 1/20 | 1/21 |
| DyspepsiaGastrointestinal disorders | 1/22 | 0/20 | 1/20 | 1/21 |
| FatigueGeneral disorders | 0/22 | 0/20 | 1/20 | 0/21 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 0/22 | 1/20 | 0/20 | 0/21 |
| Gastrointestinal Stromal TumorNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/22 | 1/20 | 0/20 | 0/21 |
| Age, Continuous(years) | Sequence BCAD | Sequence ABDC | Sequence CDBA | Sequence DACB | Total |
|---|---|---|---|---|---|
| Mean | 43.2 ± 3.54 | 56.8 ± 7.22 | 49.7 ± 13.92 | 55.3 ± 7.79 | 51.3 ± 9.98 |
| Sex: Female, Male(Participants) | Sequence BCAD | Sequence ABDC | Sequence CDBA | Sequence DACB | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 3 | 4 | 12 |
| Male | 4 | 3 | 3 | 2 | 12 |
| Race (NIH/OMB)(Participants) | Sequence BCAD | Sequence ABDC | Sequence CDBA | Sequence DACB | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 | 2 |
| White | 5 | 3 | 6 | 5 | 19 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Sequence BCAD | Sequence ABDC | Sequence CDBA | Sequence DACB | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 5 | 2 | 14 |
| Not Hispanic or Latino | 2 | 3 | 1 | 4 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Sequence BCAD | Sequence ABDC | Sequence CDBA | Sequence DACB | Total |
|---|---|---|---|---|---|
| United States | 6 | 6 | 6 | 6 | 24 |
| BMI(kg/mˆ2) | Sequence BCAD | Sequence ABDC | Sequence CDBA | Sequence DACB | Total |
|---|---|---|---|---|---|
| Mean | 34.13 ± 5.455 | 30.67 ± 2.793 | 35.65 ± 2.935 | 32.87 ± 3.644 | 33.33 ± 4.05 |
| eGFR(mL/min/1.73 mˆ2) | Sequence BCAD | Sequence ABDC | Sequence CDBA | Sequence DACB | Total |
|---|---|---|---|---|---|
| Mean | 117.94 ± 22.065 | 114.65 ± 21.348 | 107.54 ± 16.644 | 93.43 ± 20.354 | 108.39 ± 21.161 |
| HbA1c(%) | Sequence BCAD | Sequence ABDC | Sequence CDBA | Sequence DACB | Total |
|---|---|---|---|---|---|
| Mean | 7.62 ± 1.234 | 7.33 ± 0.965 | 8.07 ± 1.102 | 6.37 ± .339 | 7.35 ± 1.108 |
1 further baseline measures are reported on the registry.
The record gives a start of May 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methionine
Elcelyx Therapeutics, Inc.